Plaintiffs: AstraZeneca AB, AstraZeneca LP, KBI-E and
Pozen
Defendants: Dr. Reddy’s Laboratories Inc. and Dr.
Reddy’s Laboratories Ltd
Case Number: 3:13-cv-00091
Date Filed: January 04, 2013
Court: New
Jersey District Court
Patents-in-Suit: US5714504, US6369085, US7411070, US6926907 and US7745466
Patent Number
Current Assignee[*]
|
Issued
Date
|
Expiration
Date[†]
|
Case
Type
|
Title
|
|
Feb 03, 1998
|
Feb 03, 2015
|
Infringement
|
Compositions
|
|
Apr 09, 2002
|
May 30, 2017
|
Infringement
|
Form of S-omeprazole
|
AstraZeneca
AB (as per face page)
|
Aug 12, 2008
|
May 30, 2017
|
Infringement
|
Form of S-omeprazole
|
|
Aug 09, 2005
|
May 31, 2022
|
Infringement
|
Pharmaceutical compositions for the
coordinated delivery of NSAIDs
|
AstraZeneca
AB
(as per
face page)
|
Jun 29, 2010
|
May 30, 2017
|
Declaratory Judgment
|
Form of S-omeprazole
|
Table information sourced from
Maxval’s Assignment
Database.
KBI-E
is exclusive licensee of the ’466, ‘070, ‘085 and ‘504 patents.
About the Parties:
AstraZeneca AB manufactures and distributes
pharmaceutical products. It also undertakes research and development
activities. The company was founded in 1913 and formerly known as Astra AB.
AstraZeneca AB operates as a subsidiary of AstraZeneca plc.
AstraZeneca LP is a pharmaceutical company engaged in
discovering, developing, producing, and marketing medications. It offers
gastrointestinal, cardiovascular/metabolic, neuroscience, mental illness,
respiratory, oncology, and infectious disease medicines. The company was
founded in 1912 and operates as a subsidiary of AstraZeneca plc.
Pozen
is a pharmaceutical company that develops products for the treatment of acute
and chronic pain and other pain-related conditions in the United States. Its
products include Treximet and VIMOVO. It
has collaborations with AstraZeneca AB for the development and
commercialization of proprietary fixed dose combinations of the proton pump
inhibitor esomeprazole magnesium with the NSAID naproxen.
Dr. Reddy’s Laboratories (DRL) is an integrated pharmaceutical company
focused on providing medicines through its three business segments: Global
Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment
and Proprietary Products segment. Dr. Reddy's manufactures and markets a wide
range of pharmaceuticals in India and overseas.
As in Complaint:
AstraZeneca
LP is the current holder[‡] of New Drug Application (NDA) no. 022511 for Vimovo®
delayed release tablets (source: Maxval’s
Patent
Marker)
that is approved by FDA.
Vimovo (see Fig. 1) contains a combination of esomeprazole and naproxen. It
works by reducing substances in the body that cause inflammation, pain, and
fever and decreases the amount of acid produced in the stomach. Plaintiffs allege
that DRL seeks FDA approval to market a generic
version of Vimovo® delayed release tablets with the Abbreviated New Drug
Application (ANDA) no. 204206 that infringes the above patents.
Other Cases Filed:
Plaintiffs
and Defendants have together or individually filled cases against each other. Cases
highlighted in complaint are follows:
Plaintiff
|
Defendant
|
Case
Number
|
Date
Filed
|
Status
|
AstraZeneca AB
|
Dr.
Reddy’s Labs Inc.
|
Apr 21, 2011
|
Pending
|
|
AstraZeneca AB
|
Dr.
Reddy’s Labs, Ltd and Dr. Reddy’s Labs, Inc.
|
Jan 17, 2008
|
Closed
|
|
AstraZeneca UK and AstraZeneca LP
|
Dr. Reddy’s Labs, Ltd and Dr. Reddy’s
Labs,
Inc.
|
Jun 27, 2008
|
Pending
|
|
Dr. Reddy’s Labs Ltd and Dr. Reddy’s Labs Inc.
|
AstraZeneca
AB
|
May 19,
2008
|
Closed
|
If you are interested in knowing more about
the cases filed, please contact us.
To
get alerts on cases filed, subscribe to our Litigation Alerts.
[*] MaxVal offers Patent Assignment Alert service where subscribers
receive email alerts when assignments relating to target applications, patents
or entities of interest are recorded.
[†] Expected expiration date. Patent Term
Estimator is a free web-based tool that automatically calculates patent terms and
expiration dates for U.S. utility patents.
[‡] Patent
Marker provides an online environment for patentees to virtually mark products
and search for patent related information.
No comments:
Post a Comment